Clinical Trials Logo

Clinical Trial Summary

To achieve TB control, innovative case finding interventions are needed that will reach the broader affected population including those that do not access the health facilities. Systematic community case finding with highly sensitive screening and diagnostic tools are needed. At the facility level, the index of suspicion for TB by health care workers needs to be raised to ensure that all those that need TB screening are appropriately screened.

Clinical Trial Description

The purpose of this study is to initiate sustained, active health facility and community-based case finding interventions to achieve improved TB case detection in high burden settings (Zambia) and contribute to TB control.

The interventions are expected to increase the impact of Xpert on TB case finding, thus increase TB case detection through scaling up of a combination of community level and facility level TB case finding interventions. The study will generate evidence on the added value of using Chest X-ray (CXR) screening at community level, whilst also comparing the performance of CXR with computer assisted diagnosis (CAD) and C-reactive protein (CRP) and symptoms as screening tools in terms sensitivity, specificity and cost effectiveness. Symptom screen alone has been shown to be suboptimal for screening as it misses a significant percentage of TB due to atypical presentation of TB in HIV-infected populations. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03497195
Study type Interventional
Source University of Alabama at Birmingham
Contact Stewart Reid, MD, MPH
Phone 260966747677
Status Recruiting
Phase N/A
Start date July 1, 2018
Completion date May 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT03767946 - Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT02729571 - Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults Phase 1/Phase 2
Completed NCT02536768 - Evaluation of South Africa's National Adherence Strategy N/A
Terminated NCT02532036 - MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection Phase 1
Completed NCT02774993 - Doxycycline in Human Pulmonary Tuberculosis Phase 2
Completed NCT01934309 - Do Clinical Decision-support Reminders for Medical Providers Improve the Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya? N/A
Completed NCT01408914 - Trial of High-Dose Rifampin in Patients With TB Phase 2
Completed NCT01450085 - Chepetsa TB - Reducing TB Among HIV-Infected Malawians N/A
Completed NCT01683773 - Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A Phase 1
Completed NCT01642888 - A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI Phase 3
Completed NCT02701439 - SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting N/A
Completed NCT01674218 - Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers Phase 1
Recruiting NCT01436929 - Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs N/A
Completed NCT01497769 - Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route Phase 1